Ionis Pharmaceuticals, Inc. (IONS) has a consensus analyst rating of Buy, based on 32 analysts covering the stock. Of those, 20 recommend buying, 12 recommend holding, and 0 recommend selling.
The analyst consensus price target for IONS is $96.40, representing a +25.6% upside from the current price of $76.76. Price targets range from a low of $87.00 to a high of $103.00.
